New 384-well Assay From Affymetrix (Santa Clara, California) Delivers High-Throughput, PCR-free Gene Expression Analysis
SANTA CLARA, Calif., September 22, 2015 –Affymetrix (Nasdaq: AFFX) announces the extension of its QuantiGene® Singleplex Assay for PCR-free gene expression measurement to include a 384-well format that is easily automatable for high-throughput compound screening. The easy-to-use, high-sensitivity assay measures gene expression with minimal sample preparation, using branched DNA for signal amplification. A key feature of the assay is that it does not require RNA or DNA purification, reverse transcription, or PCR amplification, so biases and sample losses resulting from these preparation steps are eliminated. This robust assay, also available in a 96-well format, can directly detect gene expression changes as small as 10 percent. The Z-factors of the QuantiGene Singleplex HT Assay are consistently higher than those of other assay types such as qPCR.
Ideal applications for QuantiGene Singleplex HT Assay include compound screening in drug discovery, biomarker validation, and siRNA knockdown studies. The assay accommodates a range of sample types, including heavily degraded and cross-linked RNA in FFPE samples and RNA in blood.
“This new, automation-friendly 384-well assay format fits with current workflows because cells are most commonly cultured in 384-well plates for high-throughput screening,” commented Brian McLucas, product manager for Affymetrix.
“Furthermore, the limiting step with qPCR is RNA purification, which is completely avoided with QuantiGene assays. Gene expression-based high-throughput screening of hundreds of thousands of compounds can be carried out in just weeks.” About Affymetrix
Affymetrix provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 94,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, San Diego, Vienna, and Singapore. Affymetrix has about 1,100 employees and maintains sales and distribution operations worldwide. For more information about Affymetrix, please visit www.affymetrix.com
Help employers find you! Check out all the jobs and post your resume.
Ideal applications for QuantiGene Singleplex HT Assay include compound screening in drug discovery, biomarker validation, and siRNA knockdown studies. The assay accommodates a range of sample types, including heavily degraded and cross-linked RNA in FFPE samples and RNA in blood.
“This new, automation-friendly 384-well assay format fits with current workflows because cells are most commonly cultured in 384-well plates for high-throughput screening,” commented Brian McLucas, product manager for Affymetrix.
“Furthermore, the limiting step with qPCR is RNA purification, which is completely avoided with QuantiGene assays. Gene expression-based high-throughput screening of hundreds of thousands of compounds can be carried out in just weeks.” About Affymetrix
Affymetrix provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 94,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, San Diego, Vienna, and Singapore. Affymetrix has about 1,100 employees and maintains sales and distribution operations worldwide. For more information about Affymetrix, please visit www.affymetrix.com
Help employers find you! Check out all the jobs and post your resume.